Neuropathic lower back pain Musculoskeletal Diseases Dorsalgia
Conditions
Interventions
Patients will be randomised to receive a topical dose of Neuract® or placebo.
For each treatment arm, a pre-packaged single dose, approximately 1ml, will be applied. The pain reduction effects will be
Sponsors
Origin Biomed, Inc (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. At least 21 years old 2. Diagnosed with neuropathic lower back pain for at least 3 months 3. Pain at or more than level 5 but no more than 9 on a 0-10 scale 4. Score at least 6 of 10 on the modified DN4 questionnaire 5. Normal cognitive and communication skills
Exclusion criteria
Exclusion criteria: 1. Pregnant, breastfeeding or planning on becoming pregnant in the next 3 months 2. Previous adverse reaction to use of topical analgesic 3. Current use of topical analgesic on lower back area 4. Evidence of other types of pain as, or more severe, than the pain under study 5. Diagnosis of psychological disorder requiring treatment 6. History of eczema/atopy/anaphylaxis or unusual skin reactions 7. Self reported sensitivity to perfumes, essential oils, odors 8. Changes to current pain management regime within the previous 30 days prior to start of study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of pain on a 0-10 visual scale, measured 30 minutes before and after the application of of the treatment, and every hour thereafter for 8 hours. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of pain reduction | — |
Countries
United States of America
Outcome results
None listed